Bispecific antibodies against ceacam5 and cd3

A method of treating cancer, comprising administering an effective amount of a bispecific antibody comprising a first binding part, specifically binding to human CEACAM5, and a second binding part, specifically binding to human CD3ε to a subject in need thereof, wherein:

• a) the first binding part comprises a heavy chain variable region (VH), which comprises a CDRH1 of SEQ ID NO:
• 2, a CDRH2 of SEQ ID NO:
• 3 and a CDRH3 of SEQ ID NO:
• 4,
• b) the first binding part comprises a light chain variable region (VL) comprising
• b1) a CDRL1 of SEQ ID NO:
• 32, CDRL2 of SEQ ID NO:
• 33, and CDRL3 of SEQ ID NO:
• 34,
• b2) a CDRL1 of SEQ ID NO:
• 81, CDRL2 of SEQ ID NO:
• 82, and CDRL3 of SEQ ID NO:
• 83,
• b3) a CDRL1 of SEQ ID NO:
• 84, CDRL2 of SEQ ID NO:
• 85, and CDRL3 of SEQ ID NO:
• 86,
• b4) a CDRL1 of SEQ ID NO:
• 87, CDRL2 of SEQ ID NO:
• 88, and CDRL3 of SEQ ID NO:
• 89,
• b5) a CDRL1 of SEQ ID NO:
• 90, CDRL2 of SEQ ID NO:
• 91, and CDRL3 of SEQ ID NO:
• 92,
• b6) a CDRL1 of SEQ ID NO:
• 93, CDRL2 of SEQ ID NO:
• 94, and CDRL3 of SEQ ID NO:
• 95,
• b7) a CDRL 1 of SEQ ID NO:
• 96, CDRL2 of SEQ ID NO:
• 97, and CDRL3 of SEQ ID NO:
• 98,
• b8) a CDRL1 of SEQ ID NO:
• 99, CDRL2 of SEQ ID NO:
• 100, and CDRL3 of SEQ ID NO:
• 101,
• b9) a CDRL1 of SEQ ID NO:
• 102, CDRL2 of SEQ ID NO:
• 103, and CDRL3 of SEQ ID NO:
• 104,
• b10) a CDRL1 of SEQ ID NO:
• 105, CDRL2 of SEQ ID NO:
• 106, and CDRL3 of SEQ ID NO:
• 107,
• b11) a CDRL1 of SEQ ID NO:
• 108, CDRL2 of SEQ ID NO:
• 109, and CDRL3 of SEQ ID NO:
• 110, or
• b12) a CDRL1 of SEQ ID NO:
• 111, CDRL2 of SEQ ID NO:
• 112, and CDRL3 of SEQ ID NO:
• 113,
• c) the second binding part comprises a VH comprising a CDRH1 of SEQ ID NO:
• 2, CDRH2 of SEQ ID NO:
• 3 and CDRH3 of SEQ ID NO:
• 4, and
• d) the second binding part comprises a VL comprising a CDRL1 of SEQ ID NO:
• 18, CDRL2 of SEQ ID NO:
• 19, and CDRL3 of SEQ ID NO:
• 20 to a subject in need thereof.